Background: Microbiota-based treatments have shown promise to reduce recurrence for recurrent Clostridioides difficile infections (rCDI), but consistent and reliable safety data are needed to support regulatory approvals and broaden patient access. Here we provide cumulative safety data from 5 prospective clinical studies evaluating RBX2660—a standardized, microbiota-based investigational live biotherapeutic—for reducing rCDI. Methods: This analysis included […]

Background: Recurrent Clostridioides difficile infection (rCDI) is an urgent public health threat. RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic that has been evaluated in 5 prospective clinical trials. Eligibility criteria in clinical trials are often narrowly defined, excluding broader patient populations. Herein, we report a retrospective analysis of safety and efficacy of RBX2660 […]

Background: Duplicate as-needed (referred to hereafter as “PRN”) orders for common indications such as pain, nausea, insomnia, and constipation are frequent in hospitalized patients. Without explicit instructions for circumstances or order of administration, therapeutic duplication can cause confusion for nurses and violates both Join Commission and the Centers for Medicare & Medicaid Services (CMS) guidelines. […]

Background: Patients with cardiac arrest, either with a shockable or non-shockable rhythm, are at high risk of death and neurological impairment. Hypoxic-anoxic brain injury is a major cause of morbidity and mortality in these patients. (1) International Liaison Committee on Resuscitation (ILCOR) recommends moderate therapeutic hypothermia (32°C to 36°C) for patients who achieve return of […]

Background: Healthcare costs in the United States are exorbitant and excessive lab utilization contributes significantly1. Daily labs (DL), typically consisting of basic metabolic panels (BMPs) and complete blood counts (CBC) are often over-ordered for hospital inpatients2. This leads to increased costs, limits phlebotomy resources, iatrogenic anemia, patient discomfort and interruption of sleep3. The Choosing Wisely® […]

Background: Effective communication at hospital discharge between inpatient and outpatient providers is critical to improving transitions of care and reducing hospital readmissions. A key part of transitions communication is the hospital discharge summary (DCS). Prior studies show that DCSs are often not available to primary care providers (PCPs) at the time of hospital follow-up and […]

Case Presentation: This patient is an 81 year old female with a history of chronic lymphocytic leukemia and small lymphocytic lymphoma who presented to the hospital’s emergency department 5 to 6 months after the initiation of ibrutinib with a diffuse, highly pruritic, erythematous, blanchable papular rash distributed across her trunk and upper right extremity. Initially […]

Background: Catheter associated urinary tract infection (CAUTI) is a leading cause of hospital acquired infections. In this analysis, we aim to examine the incidence of CAUTI over the last 8 years and potential social determinants of health that lend to increasing mortality and morbidity during inpatient hospitalizations. Methods: Patient data was collected for years 2011-2018 […]

Background: Catheter Associated Urinary Tract Infections (CAUTI) and Central Line Associated Bloodstream Infections (CLABSI) carry a huge health care burden and is associated with increased length of stay and potential harm for the patient. There is an estimated total healthcare cost of $896 per infection for CAUTI and $45,814 per infection associated with CLABSI. The […]

Background: Treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP) due to multi-drug resistant (MDR) Gram-negative uropathogens (e.g., extended-spectrum ß-lactamase (ESBL)-producing and fluoroquinolone-resistant strains) is associated with poor outcomes and increase costs of care. In the setting of limited alternative oral options, patients with cUTI/AP are commonly hospitalized to receive intravenous (IV) antibiotic […]